FindTrial
Sign In

Investigation of Antioxidant Stress of Puerarin Treatment to Patients with Obese Polycystic Ovary Syndrome

Investigation of Antioxidant Stress of Puerarin Treatment to Patients with Obese Polycystic Ovary Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026220
Enrollment
Unknown
Registered
2019-09-27
Start date
2014-01-01
Completion date
Unknown
Last updated
2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome

Interventions

Obesity PCOS treatment group:puerarin
Obese PCOS control group:Blank
Thin PCOS treatment group:puerarin

Sponsors

Yuebei People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 39 Years

Inclusion criteria

Inclusion criteria: (1) Few ovulation or no ovulation; (2) clinical manifestations and/or hyperandrogenemia; (3) ovarian polycystic change: one side or bilateral ovarian diameter of 2 ~ 9mm follicles >=12, and (or) ovarian volume >=10ml; Meet two items of diagnostic criteria, including obese PCOS (BMI>=24, WHR >0.85) and thin PCOS

Exclusion criteria

Exclusion criteria: The adrenal and ovarian tumors in kaohsiung were excluded. Did not take contraceptives, antioxidant drugs or other drugs that affect reproductive endocrine, glucose and lipid metabolism in recent 3 months.

Design outcomes

Primary

MeasureTime frame
testosterone;Sex hormone binding globulin;prolactin;Estrone (E1)/estradiol (E2) > 1;Luteinizing hormone (LH)/follicle-stimulating hormone (FSH) >=2 ~ 3;HOMA-IR;HOMA-IS;HOMA-beta;Total cholesterol;triglycerides;High density lipoprotein cholesterol;LDL cholesterol;Superoxide dismutase;catalase;Glutathione peroxidase;Vitamin C;Vitamin E;—

Countries

China

Contacts

Public ContactLi Wenjing

Yuebei People's Hospital

maya8301112@163.com+86 13435128312

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026